A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

ClinicalTrials.gov ID: NCT00273039

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00273039. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

Study identification

NCT ID: NCT00273039
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 242 participants

Conditions and interventions

Conditions

Interventions

paroxetine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2005 (Type not available)
Primary completion: Sep 2006 (Actual)
Completion: Sep 2006 (Actual)
Last update posted: Oct 26, 2016

2005 – 2006

United States locations

U.S. sites: 14
U.S. states: 9
U.S. cities: 13

Facility	City	State	ZIP	Site status
GSK Investigational Site	Beverly Hills	California	90210	—
GSK Investigational Site	Burbank	California	91506	—
GSK Investigational Site	Jacksonville	Florida	32216	—
GSK Investigational Site	Miami	Florida	33125	—
GSK Investigational Site	North Miami	Florida	33161	—
GSK Investigational Site	Orlando	Florida	32806	—
GSK Investigational Site	Smyrna	Georgia	30080	—
GSK Investigational Site	Oakbrook Terrace	Illinois	60181	—
GSK Investigational Site	Rockville	Maryland	20852	—
GSK Investigational Site	New York	New York	10021	—
GSK Investigational Site	New York	New York	10024	—
GSK Investigational Site	Oklahoma City	Oklahoma	73104	—
GSK Investigational Site	Philadelphia	Pennsylvania	19149	—
GSK Investigational Site	Lake Jackson	Texas	77566	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00273039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 26, 2016 · Synced Nov 15, 2026